Merck says Keytruda injection on par with approved IV version in trial
Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently ...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
MarketWatch6m
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co.’ Inc.’s stock MRK rose 2% premarket Tuesday, after the company reported positive results for a new formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck said a ...